How does APOE4 cause Alzheimer's?
APOE4 does not cause Alzheimer's alone. It raises risk, and research points to five routes: amyloid, tau, immune cells, cholesterol and blood vessels.
Key takeaways · TL;DR
APOE4 does not cause Alzheimer's alone. It raises risk, and research points to five routes: amyloid, tau, immune cells, cholesterol and blood vessels.
By Dr. Kevin Tran, Doctor of Pharmacy · Last updated: October 24, 2026
APOE4 does not cause Alzheimer's on its own. It raises the risk. The APOE gene makes apolipoprotein E, a major cholesterol carrier that supports fat transport and injury repair in the brain (Liu, 2013). APOE4 does several of the brain's upkeep jobs less well, fat transport among them. A major way it raises risk is by driving earlier and heavier amyloid build-up. It also affects tau damage, the brain's immune cells and blood vessels (Yamazaki, 2019). Research is still working out which route matters most.
What APOE does when it works well
The APOE gene holds the instructions for a protein called apolipoprotein E (apoE). In the body, apoE combines with fats to form lipoproteins, which package cholesterol and other fats and carry them through the bloodstream (MedlinePlus). In the brain, apoE is a major cholesterol carrier that supports fat transport and repair after injury (Liu, 2013). Moving fats is its main job in both places (Raulin, 2022).
The gene comes in three common versions: APOE2, APOE3 and APOE4. APOE3 is the most common, found in more than half of people (MedlinePlus). Compared with APOE3, APOE4 raises the risk of Alzheimer's disease and APOE2 lowers it (Liu, 2013). Reviewers call APOE the strongest and most prevalent genetic risk factor for Alzheimer's (Raulin, 2022).
Five routes from APOE4 to Alzheimer's
The research points to five routes. They overlap, and much of the detail comes from mice and lab-grown human cells.
Route | What APOE4 does | Main evidence |
|---|---|---|
Amyloid | Earlier and heavier amyloid build-up | People (brain scans, spinal fluid); mice |
Tau | More tau-driven damage to nerve cells | Mice |
Immune cells | Brain immune cells load up with fat droplets | Human brain tissue; lab-grown cells |
Cholesterol and myelin | Cholesterol ends up in the wrong place in the cells that build myelin | Human brain tissue; lab-grown cells; mice |
Blood vessels | A leakier blood-brain barrier | People who carry APOE4 |
1. Amyloid: earlier and heavier build-up
APOE4 goes with more of the protein clumps called amyloid plaques in the brains of people with Alzheimer's (MedlinePlus). Reviewers name this as a major way APOE4 raises risk: it drives earlier and more abundant amyloid (Yamazaki, 2019). ApoE helps seed the plaques, and apoE4 drives them earlier and in greater amounts (Raulin, 2022).
The apoE versions also handle how amyloid clumps and clears in different ways (Liu, 2013). In young mice carrying human apoE, how fast soluble amyloid cleared from brain fluid depended on the apoE version, while amyloid production did not differ (Castellano, 2011).
You can see the shift in people. A meta-analysis of 55 studies measured amyloid by PET scan or spinal fluid in 2,914 people whose thinking was normal. The age at which 15 in 100 had amyloid was about 40 with 4/4, 50 with 2/4, 55 with 3/4, 65 with 3/3 and 95 with 2/3 (Jansen, 2015).
2. Tau: more damage to nerve cells
In mice engineered to build up the tau protein, those carrying human APOE4 developed markedly more brain shrinkage and inflammation than those carrying APOE2 or APOE3. Mice with no apoE at all were largely protected, and the effect did not depend on amyloid (Shi, 2017). Reviewers describe growing evidence that APOE shapes tau damage in Alzheimer's (Yamazaki, 2019).
3. The brain's immune cells
In brain tissue from people with Alzheimer's, immune cells called microglia that carry fat droplets (marked by an enzyme called ACSL1) were most common in people with 4/4. In lab-grown human microglia, amyloid switched on ACSL1 and fat droplets built up, depending on the APOE version. Fluid from these fat-laden cells made nerve cells build up altered (phosphorylated) tau and damaged them (Haney, 2024). In cultured microglia, cells expressing APOE4 showed a stronger immune response to an inflammatory trigger (Shi, 2017).
4. Cholesterol and myelin
In post-mortem human brains, APOE4 went with cholesterol deposited in the wrong place in oligodendrocytes, the cells that make the myelin around nerve fibers, and with less myelin. The team confirmed the problem in lab-grown human cells and in mice carrying human APOE4. In those mice, helping cholesterol move with a drug compound increased myelin and improved learning and memory (Blanchard, 2022).
5. Blood vessels and the blood-brain barrier
APOE4 carriers showed breakdown of the blood-brain barrier in the hippocampus and medial temporal lobe. It was visible in carriers whose thinking was still normal, and more severe in those with cognitive impairment. It was not related to amyloid or tau measured in spinal fluid or on PET scans. In carriers, higher levels of a spinal-fluid marker of injury to pericytes, cells of the blood-brain barrier, predicted later cognitive decline, even after accounting for amyloid and tau (Montagne, 2020). APOE4 also goes with a higher risk of cerebral amyloid angiopathy (amyloid in the brain's blood vessels) (Liu, 2013).
And more jobs
The reviews name other jobs where the apoE versions differ, or where APOE4 is harmful or less efficient: sugar use by the brain (glucose metabolism), signaling between nerve cells, the connections between nerve cells (synapses), mitochondria and inflammation (Liu, 2013; Yamazaki, 2019).
How to read this. Mice and lab-grown cells show how a route can work, not how much it matters in any one person. The human studies show links. And APOE4 raises risk; it does not decide it. Not everyone with APOE4 develops Alzheimer's, and not everyone with Alzheimer's has APOE4 (MedlinePlus). For the separate question of age at onset, see whether APOE4 causes early-onset Alzheimer's.
Why researchers have not picked one route
The routes are not one simple chain. APOE4 is either harmful or less efficient in several of the brain's upkeep pathways at once (Yamazaki, 2019). Two of the routes ran apart from amyloid: tau damage in the mice (Shi, 2017) and blood-brain barrier breakdown in people (Montagne, 2020). The reviewers also note that apoE's complex biology makes treatments aimed at it hard to design (Raulin, 2022).
What this means if you carry APOE4
Your genotype is fixed. Some of these routes touch things you can measure and change.
Blood fats. Moving fats is APOE's main job, and APOE4 shows up in your blood fats too. In a pooled analysis of 82 studies (86,067 healthy people), LDL cholesterol rose in a roughly straight line across APOE genotypes, and people with 4/4 had LDL about 44 mg/dL higher than people with 2/2 (Bennet, 2007). APOE4 is also linked to more atherosclerosis, the artery narrowing behind heart attacks and strokes (MedlinePlus).
Sugar and inflammation. Both are on the review's list of brain pathways where the apoE versions differ (Liu, 2013).
Phoenix targets blood fats, blood sugar, inflammation, sleep and other levers that carriers can measure and change. Members read their own blood numbers against APOE4 targets, such as ApoB, and see whether what they do moves them. Some target lines come from guidelines and some are Phoenix's own choices, and none has been tested in APOE4 carriers, as the lab targets page says. On Phoenix, 89% see improvement in key APOE4 biomarkers within 3 months. Phoenix earns revenue only from your membership, never from anything we recommend.
Frequently asked questions
Does everyone with APOE4 get Alzheimer's?
No. Not everyone who carries APOE4 develops the disease, and not everyone with Alzheimer's carries it (MedlinePlus). The odds by genotype are on the risk by age page.
What does the APOE gene do?
It makes apolipoprotein E, a protein that combines with fats to form lipoproteins, which package cholesterol and other fats and carry them through the bloodstream (MedlinePlus). In the brain, it is a major cholesterol carrier that supports repair after injury (Liu, 2013).
Do two copies work differently from one?
Several studies show a stronger signal with two copies. In people with normal thinking, amyloid reached 15 in 100 at about age 40 with 4/4, against 55 with 3/4 (Jansen, 2015). Among people with Alzheimer's, fat-laden microglia were most common in those with 4/4 (Haney, 2024). In pathology data, almost all people with 4/4 showed Alzheimer's brain changes, and the authors describe two copies as a distinct genetic form of the disease (Fortea, 2024). Brain changes are not the same as symptoms: amyloid is common in people whose thinking is normal (Jansen, 2015).
Does APOE4 affect the heart too?
Yes. APOE4 goes with higher LDL cholesterol (Bennet, 2007) and is linked to more atherosclerosis, which raises the risk of heart attack and stroke (MedlinePlus).
Is there a treatment aimed at APOE4 itself?
Researchers are working on it. Recent reviews discuss targeting APOE with a precision-medicine approach (Yamazaki, 2019) and note that apoE's complex biology makes such treatments hard to design (Raulin, 2022).
Is this medical advice?
No. Phoenix educates. Your doctor decides your treatment.
Sources
Liu, Nat Rev Neurol 2013: Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Haney, Nature 2024: APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia
Blanchard, Nature 2022: APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes
Montagne, Nature 2020: APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline
Fortea, Nat Med 2024: APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease
Bennet, JAMA 2007: Association of apolipoprotein E genotypes with lipid levels and coronary risk
Phoenix is a community of 750+ APOE4 carriers. If you carry APOE4, apply to join Phoenix (60-day money-back guarantee).
This is not medical advice. Phoenix educates. Your doctor decides your treatment.
Dr. Kevin Tran
Doctor of PharmacyDr. Kevin Tran is a Doctor of Pharmacy and APOE4/4 carrier dedicated to helping others with the APOE4 gene variant take proactive steps for their health. He founded The Phoenix Community to provide evidence-based resources and support for APOE4 carriers.
View all articles→